Clinical Trial: WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Obesity & Overweight
Study Type: OBSERVATIONAL
Official Title: WeDosify Real-World Evidence: Evaluating a Clinical Decision Support and Patient Engagement Tool for Personalized Semaglutide Dosing in Adults With Overweight or Obesity in the United States
Brief Summary:
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.
Read more